The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 7, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | Option exercise(M) | 1K | — | $0 |
| Jul 7, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | Sell(S) | 1K | $25.00 | $27K |
| Jul 7, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | Option exercise(M) | 1K | $12.92 | $14K |
| Jul 7, 2026 | Barchas Isaac | Director | Sell(S) | 17K | $24.20 | $409K |
| Jul 6, 2026 | Barchas Isaac | Director | Sell(S) | 83K | $24.11 | $2.0M |
| Jul 2, 2026 | Barchas Isaac | Director | Sell(S) | 76K | $22.35 | $1.7M |
| Jul 2, 2026 | Barchas Isaac | Director | Sell(S) | 24K | $23.33 | $568K |
| Jul 2, 2026 | Lechleider Robert | Chief Medical Officer | Option exercise(M) | 55K | $8.73 | $480K |
| Jul 2, 2026 | Lechleider Robert | Chief Medical Officer | Sell(S) | 23K | $21.95 | $499K |
| Jul 2, 2026 | Lechleider Robert | Chief Medical Officer | Sell(S) | 16K | $22.76 | $369K |
| Jul 2, 2026 | Lechleider Robert | Chief Medical Officer | Sell(S) | 16K | $23.44 | $377K |
| Jul 2, 2026 | Lechleider Robert | Chief Medical Officer | Option exercise(M) | 55K | — | $0 |
| Jun 30, 2026 | Barchas Isaac | Director | Sell(S) | 101K | $21.12 | $2.1M |
| Jun 25, 2026 | Lechleider Robert | Chief Medical Officer | Option exercise(M) | 55K | $8.73 | $480K |
| Jun 25, 2026 | Lechleider Robert | Chief Medical Officer | Sell(S) | 41K | $19.56 | $794K |
| Jun 25, 2026 | Lechleider Robert | Chief Medical Officer | Sell(S) | 14K | $20.66 | $298K |
| Jun 25, 2026 | Lechleider Robert | Chief Medical Officer | Option exercise(M) | 55K | — | $0 |
| Jun 15, 2026 | Rosett Max | Chief Financial Officer | Option exercise(M) | 60K | $1.05 | $63K |
| Jun 15, 2026 | Rosett Max | Chief Financial Officer | Sell(S) | 60K | $18.23 | $1.1M |
| Jun 15, 2026 | Rosett Max | Chief Financial Officer | Option exercise(M) | 60K | — | $0 |
| Jun 10, 2026 | Barchas Isaac | Director | Grant(A) | 10K | — | $0 |
| Jun 10, 2026 | Schafer Carol | Director | Grant(A) | 10K | — | $0 |
| Jun 10, 2026 | Wagenheim Philip | Director | Grant(A) | 10K | — | $0 |
| Jun 10, 2026 | Swain Sandra M | Director | Grant(A) | 10K | — | $0 |
| Jun 10, 2026 | Bienaime Jean Jacques | Director | Grant(A) | 10K | — | $0 |
| Jun 10, 2026 | Boylan James P | Director | Grant(A) | 10K | — | $0 |
| Jun 5, 2026 | Bienaime Jean Jacques | Director | Sell(S) | 500 | $19.44 | $10K |
| Jun 5, 2026 | Bienaime Jean Jacques | Director | Sell(S) | 10K | $19.41 | $194K |
| Jun 5, 2026 | Bienaime Jean Jacques | Director | Buy(P) | 6K | $19.48 | $117K |
| Jun 5, 2026 | Bienaime Jean Jacques | Director | Buy(P) | 4K | $19.46 | $68K |
| Jun 5, 2026 | Bienaime Jean Jacques | Director | Buy(P) | 1K | $19.27 | $19K |
| May 15, 2026 | Bienaime Jean Jacques | Director | Buy(P) | 5K | $20.70 | $104K |
| Apr 2, 2026 | Higgins Jack | Chief Scientific Officer | Sell(S) | 9K | $21.64 | $204K |
| Apr 2, 2026 | Rosett Max | Chief Financial Officer | Option exercise(M) | 32K | $1.05 | $33K |
| Apr 2, 2026 | Rosett Max | Chief Financial Officer | Option exercise(M) | 40K | $1.35 | $54K |
| Apr 2, 2026 | Rosett Max | Chief Financial Officer | Sell(S) | 64K | $21.91 | $1.4M |
| Apr 2, 2026 | Rosett Max | Chief Financial Officer | Sell(S) | 1K | $22.48 | $30K |
| Apr 2, 2026 | Rosett Max | Chief Financial Officer | Option exercise(M) | 32K | — | $0 |
| Apr 2, 2026 | Rosett Max | Chief Financial Officer | Option exercise(M) | 40K | — | $0 |
| Mar 30, 2026 | Higgins Jack | Chief Scientific Officer | Gift(G) | 6K | — | $0 |
| Mar 27, 2026 | Siegall Clay B | President and CEO, Director | Buy(P) | 25K | $19.67 | $501K |
| Mar 23, 2026 | Wagenheim Philip | Director | Sell(S) | 28K | $20.65 | $582K |
| Mar 20, 2026 | Wagenheim Philip | Director | Sell(S) | 37K | $20.47 | $753K |
| Mar 11, 2026 | Bienaime Jean Jacques | Director | Buy(P) | 1K | $21.55 | $22K |
| Mar 10, 2026 | Bienaime Jean Jacques | Director | Buy(P) | 1K | $22.12 | $22K |
| Dec 30, 2025 | Siegall Clay B | President and CEO, Director | Buy(P) | 5K | $21.15 | $100K |
| Dec 22, 2025 | Barchas Isaac | Director | Sell(S) | 372K | $21.72 | $8.1M |
| Dec 22, 2025 | Barchas Isaac | Director | Sell(S) | 11K | $22.34 | $251K |
| Dec 19, 2025 | Siegall Clay B | President and CEO, Director | Gift(G) | 200K | — | $0 |
| Dec 19, 2025 | Siegall Clay B | President and CEO, Director | Buy(P) | 7K | $20.48 | $149K |
| Dec 19, 2025 | Higgins Jack | Chief Scientific Officer | Gift(G) | 1K | — | $0 |
| Dec 19, 2025 | Higgins Jack | Chief Scientific Officer | Gift(G) | 1K | — | $0 |
| Dec 19, 2025 | Higgins Jack | Chief Scientific Officer | Gift(G) | 1K | — | $0 |
| Dec 19, 2025 | Higgins Jack | Chief Scientific Officer | Gift(G) | 1K | — | $0 |
| Dec 19, 2025 | Higgins Jack | Chief Scientific Officer | Gift(G) | 1K | — | $0 |
| Dec 19, 2025 | Higgins Jack | Chief Scientific Officer | Gift(G) | 1K | — | $0 |
| Dec 19, 2025 | Tsai Philip | Chief Technical Officer | Buy(P) | 10K | $20.49 | $205K |
| Dec 18, 2025 | Siegall Clay B | President and CEO, Director | Buy(P) | 47K | $21.50 | $1000K |
| Sep 10, 2025 | Higgins Jack | Chief Scientific Officer | Option exercise(M) | 22K | $1.35 | $30K |
| Sep 10, 2025 | Higgins Jack | Chief Scientific Officer | Option exercise(M) | 22K | — | $0 |
| Jul 29, 2025 | Stoneman Sandra G. | CHIEF LEGAL OFFICER & GC | Grant(A) | 190K | — | $0 |
| Jul 29, 2025 | Siegall Clay B | President and CEO, Director | Grant(A) | 800K | — | $0 |
| Jul 29, 2025 | Higgins Jack | Chief Scientific Officer | Grant(A) | 196K | — | $0 |
| Jul 29, 2025 | Horn Kinney | CHIEF BUSINESS OFFICER | Grant(A) | 161K | — | $0 |
| Jul 29, 2025 | Lechleider Robert | Chief Medical Officer | Grant(A) | 242K | — | $0 |
| Jul 29, 2025 | Rosett Max | Chief Financial Officer | Grant(A) | 207K | — | $0 |
| Jul 29, 2025 | Tsai Philip | Chief Technical Officer | Grant(A) | 190K | — | $0 |
| Jun 10, 2025 | Swain Sandra M | Director | Grant(A) | 19K | — | $0 |
| Jun 10, 2025 | Bienaime Jean Jacques | Director | Grant(A) | 19K | — | $0 |
| Jun 10, 2025 | Barchas Isaac | Director | Grant(A) | 19K | — | $0 |
| Jun 10, 2025 | Wagenheim Philip | Director | Grant(A) | 19K | — | $0 |
| Jun 10, 2025 | Schafer Carol | Director | Grant(A) | 19K | — | $0 |
| Jun 10, 2025 | Boylan James P | Director | Grant(A) | 19K | — | $0 |
| Jun 3, 2025 | Bienaime Jean Jacques | Director | Buy(P) | 5K | $9.38 | $47K |
| Mar 27, 2025 | Higgins Jack | Chief Scientific Officer | Option exercise(M) | 5K | $1.35 | $7K |
| Mar 27, 2025 | Higgins Jack | Chief Scientific Officer | Option exercise(M) | 5K | — | $0 |
| Mar 26, 2025 | Siegall Clay B | President and CEO, Director | Buy(P) | 137K | $7.29 | $999K |
| Mar 25, 2025 | Bienaime Jean Jacques | Director | Buy(P) | 8K | $7.78 | $61K |
| Mar 24, 2025 | Tsai Philip | Chief Technology Officer | Buy(P) | 12K | $8.42 | $104K |
| Mar 24, 2025 | Bienaime Jean Jacques | Director | Buy(P) | 7K | $8.21 | $57K |
| Jan 31, 2025 | Siegall Clay B | President and CEO, Director | Buy(P) | 150K | $7.75 | $1.2M |
| Nov 22, 2024 | Siegall Clay B | President and CEO, Director | Buy(P) | 34K | $9.78 | $332K |
| Nov 21, 2024 | Tsai Philip | Chief Technology Officer | Buy(P) | 21K | $9.43 | $198K |
| Nov 21, 2024 | Lechleider Robert | Chief Medical Officer | Buy(P) | 16K | $9.48 | $150K |
| Nov 21, 2024 | Siegall Clay B | President and CEO, Director | Buy(P) | 66K | $9.54 | $630K |
| Sep 19, 2024 | Rosett Max | Chief Financial Officer | Sell(S) | 14K | $16.01 | $230K |
| Sep 19, 2024 | Rosett Max | Chief Financial Officer | Option exercise(M) | 42K | $1.05 | $44K |
| Sep 19, 2024 | Rosett Max | Chief Financial Officer | Option exercise(M) | 42K | — | $0 |
| Aug 19, 2024 | Higgins Jack | Chief Scientific Officer | Gift(G) | 2K | — | $0 |
| Aug 16, 2024 | Bienaime Jean Jacques | Director | Buy(P) | 7K | $13.94 | $98K |
| Aug 15, 2024 | Higgins Jack | Chief Scientific Officer | Sell(S) | 4K | $13.93 | $49K |
| Aug 15, 2024 | Higgins Jack | Chief Scientific Officer | Option exercise(M) | 20K | $1.35 | $26K |
| Aug 15, 2024 | Higgins Jack | Chief Scientific Officer | Option exercise(M) | 20K | — | $0 |
| Aug 9, 2024 | Higgins Jack | Chief Scientific Officer | Grant(A) | 190K | — | $0 |
| Aug 9, 2024 | Lechleider Robert | Chief Medical Officer | Grant(A) | 200K | — | $0 |
| Aug 9, 2024 | Rosett Max | EVP, Operations & CFO | Grant(A) | 190K | — | $0 |
| Aug 9, 2024 | Turner Bruce | Chief Strategy Officer | Grant(A) | 110K | — | $0 |
| Aug 9, 2024 | Horn Kinney | CHIEF BUSINESS OFFICER | Grant(A) | 130K | — | $0 |
| Aug 9, 2024 | Stoneman Sandra G. | CHIEF LEGAL OFFICER & GC | Grant(A) | 210K | — | $0 |
| Aug 9, 2024 | Siegall Clay B | President and CEO, Director | Grant(A) | 800K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-04-26 → 2026-07-11. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).